Title:Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors
VOLUME: 18 ISSUE: 12
Author(s):Anna Campanati, Elisa Molinelli*, Valerio Brisigotti and Annamaria Offidani
Affiliation:Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona
Keywords:Adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, anti-TNFα, efficacy, safety.
Abstract:Background: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated
global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life
and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis
of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis,
with remarkable efficacy and safety profile extensively examined and monitored.
Methods: Biological therapies currently available can be divided into three main categories: the TNFα
antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)-
12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and
safety of TNFα inhibitors largely used in the management of the cutaneous disease.
Conclusion: Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed
anti-TNFα are here discussed in detail.
